Language:
Baker McKenzie advised Allecra Therapeutics on its exclusive licensing agreement with Shanghai Haini Pharmaceutical Co., Ltd., part of the Yangtze River Pharmaceutical Group under which Haini will develop and commercialize its product EXBLIFEP (cefepime/enmetazobactam) for Greater China. Under the terms of the agreement, Allecra will receive payments and milestone fees in an amount of around USD 80 million.

Baker McKenzie advised Allecra with a cross-border team of life science lawyers led by Julia Braun on all legal aspects of the licensing including IP, Corporate, Foreign Direct Investment Control and regulatory law. The consummation of the licensing transaction is subject to regulatory approval and other customary conditions precedent.

"The agreement is a significant milestone in the development and global commercialization of Allecra's lead candidate for the treatment of Urinary Tract Infections. It is an honor for us to assist the Allecra team on this landmark license transaction following its positive top-line Phase III clinical trial results earlier this year", comments Julia Braun, Corporate/M&A counsel at Baker McKenzie, who led the transaction.

Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam, has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial, and the Company is preparing submissions for marketing approval in the U.S. and EU based on these results.

Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd. was founded on September 11, 2001. Yangzijiang Pharmaceutical has ranked first among the top 100 pharmaceutical industries in China for three consecutive years. It is the first wholly-owned subsidiary established by the group outside Taizhou. The company occupies a total area of about 280,000 square meters, a total construction area of 70,000 square meters, a greening rate of 47%, and more than 500 employees.

Baker McKenzie's Corporate / M&A and life science team regularly advises big pharma, financial investors and biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised, among others, CatalYm on a EUR 50 million Series B financing led by Vesalius Capital to advance its immunoncology development, Casdin Capital on a USD 50 million extension of the Series B Equity Financing in DNA Script, Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie, CureVac on its strategic mRNA technology collaboration with GSK, LSP on a USD 38.5 million Series B equity financing in DNA Script, Galapagos on its 10 year global research and development collaboration with Gilead, Hitachi Chemical Company, Tokyo on the take-over of German apceth Biopharma, Forbion as lead investor on a EUR 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation and Mundipharma on the acquisition of VC-backed CellAct Pharma.


Legal advisor to Allecra Therapeutics:
Baker McKenzie


Lead: Corporate/M&A: Julia Braun (counsel, Munich)

Team Germany: Corporate/M&A: Dr. Julia Rossié (associate, Munich)
                             Public Law: Anahita Thoms (partner, Dusseldorf), Alexander Ehrle (associate, Berlin)                
                             IP: Julia Schieber (senior associate, Zurich)

Team China: IP: Isabella Liu (partner, Hong Kong), Elva Yao, (associate, Shanghai)
Explore Our Newsroom